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Material and Methods: A	single-	center	retrospective	epilepsy	cohort	from	the	decade	
of	2004–2013	was	assessed.	Poisson	regression	models	with	 robust	variance	were	
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1  | INTRODUCTION
Epilepsy	 is	 one	 of	 the	 most	 prevalent	 chronic	 neurologic	 disorders	
(World	Health	Organization,	2015).	Many	people	with	epilepsy	(PWE)	
receive	lifelong	prescription	treatment.
Older	 antiepileptic	 drugs	 (AEDs),	 mainly	 enzyme	 inducers	
(EIAEDs),	 such	 as	 carbamazepine	 (CBZ),	 phenytoin	 (PHT),	 pheno-
barbital	 (PB),	or	primidone,	may	be	associated	with	more	adverse	
effects	 than	 newer	 AEDs.	 For	 example,	 they	 alter	 lipid	 profile,	
increasing	serum	cholesterol	levels	(Mintzer	et	al.,	2009).	However,	
there	is	a	lack	of	information	about	the	prevalence	of	dyslipidemia	




2007).	 For	 these	 reasons,	 some	 authors	 have	 suggested	 start-
ing	 new	 AEDs	 in	 newly	 diagnosed	 patients	 or	 changing	 EIAEDs	
if	 patients	 experience	 metabolism-	related	 effects	 (Brodie	 et	al.,	
2013).
Higher	 prevalence	 of	 cardiovascular	 risk	 factors	 (CRFs)	 such	 as	
hypertension,	 diabetes,	 and	 high	 cholesterol	 has	 been	 reported	 in	
PWE,	 compared	 to	 general	 population	 (Elliott	 et	al.,	 2009;	 Téllez-	
Zenteno,	Matijevic,	&	Wiebe,	2005).	A	recent	review	of	comorbidity	
in	 epilepsy	 (Gaitatzis,	 Sisodiya,	 &	 Sander,	 2012)	 suggested	 a	 causal	
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association	with	 hypertension	 and	 diabetes,	 both	 of	which	 are	 risk	
factors	 for	 stroke.	As	 cerebrovascular	 disease	 accounts	 for	 approxi-
mately	30%	of	newly	diagnosed	epilepsy	in	adults	(Hauser,	Annegers,	
&	Kurland,	1993),	 that	could	 reflect	 the	causal	association	between	
these	risk	factors	and	epilepsy.	Therefore,	more	information	is	needed	











of	 this	 university	 medical	 center	 serves	 a	 population	 of	 339,196	









The	 register	 included	 only	 patients	 with	 a	 diagnosis	 of	 epilepsy	
according	to	the	2005	International	League	Against	Epilepsy	(ILAE)	
definition	(Fisher	et	al.,	2005).	To	identify	cases	for	this	study,	elec-
tronic	medical	 records	 of	 the	 patients	 attended	 in	 the	 outpatient	
clinic	with	a	diagnosis	of	epilepsy	were	revised	one-	by-	one	by	the	
principal	 investigator	 (RMVH).	 The	 international	 classification	 of	
diseases	 codification	 was	 not	 used	 because,	 at	 the	 time	 of	 data	
collection,	 it	 was	 not	 considered	 reliable.	 Etiology	 was	 assessed	
using	the	available	test	information	(CT,	MRI,	EEG)	and	classified	as	
genetic	(epilepsy	is	the	direct	result	of	a	known	or	presumed	genetic	





2010).	 Treatment	 at	 inclusion	was	 determined	 from	 prescriptions	
written	by	the	general	physician	(GP)	and	neurologist.	In	this	analy-
sis,	only	participants	older	than	35	years	were	included.	The	register	
was	approved	by	the	 local	 institutional	ethics	committee	 (Hospital	
del	 Mar-	IMIM	 2014/5505/I)	 and	 followed	 national	 and	 interna-
tional	 guidelines	 (Deontological	 Code,	 Declaration	 of	 Helsinki).	
Written	 informed	 consent	was	not	 required	 for	 this	 observational	
study.	Patient	 information	was	anonymized	and	de-	identified	prior	
to	analysis.
2.2 | Definition of cardiovascular risk factors
Diabetes	was	considered	 if	a	diagnosis	had	been	recorded	by	a	GP,	
the	 patient	was	 under	 treatment,	 or	 fasting	 glucose	was	 ≥126	mg/
dl	in	two	blood	tests	or	≥200	mg/dl	or	HbA1c	>6.5%	in	any	test	per-
formed	close	 to	 the	 inclusion	date.	Hypertension	was	considered	 if	
patients	were	diagnosed	by	a	GP,	were	under	treatment,	or	had	rest-
ing	 blood	 pressure	 measurements	 taken	 close	 to	 the	 study	 inclu-
sion	 date	 of	 systolic	 blood	 pressure	 ≥140	mmHg	 or	 diastolic	 blood	







culating	 percentages	 in	 categorical	 and	 mean	 or	 median	 with	 cor-
responding	 standard	 deviations	 and	 interquartile	 range	 (depending	
on	normal	distribution)	 in	quantitative	variables.	A	bivariate	analysis,	
using	Chi-	squared	for	categorical	variables,	and	t	test	or	ANOVA	for	


















analysis	 was	 also	 performed,	 excluding	 patients	 with	 vascular	 etiol-
ogy,	considered	likely	to	be	the	main	contributors	to	the	CRF	burden.	






Over	 a	 period	 of	 10	years,	 1,543	 patients	 were	 included	 con-
secutively	 in	 the	 register,	 of	 which	 1,045	 were	 aged	 35	years	
     |  3 of 6VIVANCO- HIDALGO et AL.













showed	 that	 patients	 receiving	 EIAEDs	 had	 36%	 higher	 preva-
lence	of	dyslipidemia,	compared	to	those	taking	non-	EIAEDs.	Only	
patients	 receiving	PHT	 showed	a	 significantly	 higher	dyslipidemia	
prevalence,	 compared	 to	 patients	 under	VPA	 (reference)	 therapy.	
After	 excluding	 vascular	 etiology	 and	 previous	 cardiovascular	
events,	 in	 the	 remaining	400	patients,	EIAEDs	 (PRa	1.45,	p	<	.05),	
and	 especially	 PHT	 (PRa	 1.77,	 p	<	.05),	 were	 still	 associated	with	
dyslipidemia	(Table	3).
3.2 | Cardiovascular risk factors and 
epilepsy etiology





hypertension	and	etiology	 lost	 its	 statistical	 significance,	although	a	







Total (N = 1,045)
Genetic (N = 123, 
11.77%)
Structural/metabolic (N = 519, 
49.67%)





52.53	(42.60–66.11) 43.8	(39.8–54.04) 53.17	(43.66–67.37) 54.96	(42.94–69.24) <.001




15.15	(1.975–33.85) 27.26	(15.23–37.22) 7.91	(0.86–28.84) 20.95	(4.92–37.11) <.001
HTA,	N	(%) 342	(32.73) 15	(12.20) 193	(37.19) 134	(33.25) <.001
DLP,	N	(%) 401	(38.37) 32	(26.02) 196	(37.76) 173	(42.93) .003
DM,	N	(%) 137	(13.11) 7	(5.69) 83	(15.99) 47	(11.66) .005
Smoking 228	(21.8) 28	(22.76) 121	(23.31) 79	(19.60) .143
IQR,	interquartile	range;	AED,	antiepileptic	drug;	HTA,	hypertension;	DLP,	dyslipidemia;	DM,	diabetes	mellitus.
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4  | DISCUSSION




EIAEDs—as	 a	 group—were	 associated	with	 dyslipidemia	 diagnosis.	
However,	only	patients	under	PHT	therapy	had	a	higher	prevalence	
of	 this	 CRF	 compared	 to	 those	 treated	with	 VPA.	 No	 differences	










cholesterol	 levels.	 In	 our	 study,	 patients	 under	VPA	 therapy	were	
less	 affected	 by	 dyslipidemia	 than	 the	 rest	 of	 the	 population.	We	
would	 speculate	 that	 the	 variety	 of	 lipid	 profile	 findings	 analyzed	
in	 the	systematic	 review	might	correspond	 to	differences	not	only	
in	 the	study	design	 (Grau	et	al.,	2007)	but	also	 in	 the	geographical	
region	or	dietary	habits.	Concerning	new	AEDs,	we	observed	 that	
the	levetiracetam	group	had	more	CRFs,	compared	to	patient	groups	
taking	 other	 drugs	 (in	monotherapy).	 However,	 after	 adjusting	 for	
several	 factors,	 the	 significance	of	 the	association	disappeared.	As	
this	was	a	cross-	sectional	 study,	 that	 result	might	be	explained	by	
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N (%) PRa N (%) PRa N (%) PRa
Inducer	vs	noninducers	AEDs
Inducer	AEDs	(155) 35	(22.58) 0.81	(0.58–1.13) 58	(37.42) 1.45	*	(1.09–1.92) 11	(7.10) 0.77	(0.40–1.48)
Individual	AEDs	with	VPA	as	reference	group
CBZ	(77) 14	(18.18) 0.69	(0.40–1.18) 24	(31.17) 1.25	(0.78–2) 5	(6.49) 1.00	(0.33–3.07)
PHT	(54) 18	(33.33) 1.07	(0.70–1.64) 25	(46.30) 1.77*	(1.15–2.73) 3	(5.56) 0.61	(0.19–1.97)
LEV	(102) 41	(40.20) 1.12	(0.79–1.58) 37	(36.27) 1.36	(0.91–2.04) 17	(16.67) 1.32	(0.65–2.67)
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Another	interesting	result	was	the	low	prevalence	of	diabetes	in	the	
EIAEDs	group.	Inconsistent	results	in	the	literature	make	us	cautious	












they	 increase	 the	 risk	of	 stroke,	which	 is	 a	 cause	of	epilepsy.	 In	our	
initial	analysis,	structural	and	unknown	etiology	were	associated	with	
higher	prevalence	of	all	three	risk	factors,	compared	to	genetic	etiol-
ogy.	 In	 the	multivariate	 analysis,	 however,	 this	 association	 remained	
only	for	hypertension.	After	excluding	vascular	epilepsy	and	previous	




































with	 other	 CRFs.	 After	 excluding	 vascular	 etiology,	 there	 were	 no	
differences	 in	CRF	prevalence	between	etiologies,	 although	a	 trend	
toward	higher	prevalence	of	hypertension	was	observed	in	structural	
and	unknown	etiologies,	compared	to	genetic	epilepsy.	Further	stud-
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